Drugs / Samuraciclib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07645651 | Oct 2026 → Jul 2027 expected | pancreatic ductal adenocarcinoma | University of Washington | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07665684 | Jul 2026 → May 2029 expected | mucinous adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06125522 | Jan 2024 → Sep 2026 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT05963997 | Oct 2023 → Mar 2026 | breast cancer | Carrick Therapeutics Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT04802759 | Jun 2021 → May 2029 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05963984 | Nov 2023 → Mar 2025 | breast cancer | Carrick Therapeutics Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-10 | Carrick Therapeutics Limited | Results Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer carricktherapeutics.com ↗
These Phase 2 trial results show that samuraciclib in combination with fulvestrant provided a very notable and clinically meaningful benefit in a broad patient population with HR positive, HER2 negative metastatic breast cancer whose disease progressed following treatment with a CDK4/6 inhibitor. |
| 2025-05-15 | Carrick Therapeutics Limited | Results Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer carricktherapeutics.com ↗
The analysis indicated that study participants with no evidence of a deleterious mutation in the TP53 gene in circulating tumor DNA at baseline or separately, without liver metastases at baseline, experienced extended durations of progression-free survival. |
| 2021-12-09 | Carrick Therapeutics Limited | Results Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium carricktherapeutics.com ↗
Samuraciclib in combination with fulvestrant in the post CDK4/6 setting has demonstrated a median mPFS of 32 weeks. |
| 2021-09-16 | Carrick Therapeutics Limited | Results Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021 carricktherapeutics.com ↗
Data presented from a Phase 2a study of samuraciclib in combination with fulvestrant in women with hormone receptor positive (HR+), HER2- advanced breast cancer (BC) previously treated with a CDK4/6 inhibitor (abstract: 1346 (265P)) demonstrated clinical activity and tolerability that supports further clinical development of the combination. |
| 2021-08-16 | Carrick Therapeutics Limited | Regulatory Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer carricktherapeutics.com ↗ |
All press releases naming this drug 14 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Samuraciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04802759 ↗ |
| Route | Oral | “360 mg orally once a day” NCT04802759 ↗ |